Form 4: Ginkgo Bioworks Director Converts Restricted Stock Units to Class A Shares

Ginkgo Bioworks Holdings, Inc. Director Kathy Hopinkah Hannan converted 10,822 restricted stock units into Class A Common Stock on June 11, 2025, as part of her compensation program.

Summary

• Kathy Hopinkah Hannan, a Director of Ginkgo Bioworks Holdings, Inc. (DNA), reported a change in her beneficial ownership.
• On June 11, 2025, she acquired 10,822 shares of Class A Common Stock through the conversion of Restricted Stock Units (RSUs).
• These RSUs were granted on June 13, 2024, and vested in full on June 11, 2025, consistent with the company's Non-Employee Director Compensation Program.
• Following this transaction, Ms. Hannan directly beneficially owns 15,003 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reports a routine, expected insider transaction related to director compensation. It's a positive sign of continued director service and alignment with shareholder interests, but does not indicate new strategic developments or significant financial performance changes.

Positives

• The transaction reflects the vesting of previously granted compensation, indicating the director's continued service and alignment with shareholder interests.
• The conversion of RSUs into common stock increases the director's direct ownership in the company, potentially signaling confidence.

Future Outlook

The document indicates that the RSU vesting was tied to the date immediately prior to the Issuer's next Annual Meeting of Shareholders, suggesting future annual meetings will continue to be a point for director compensation vesting.

Industry Context

This Form 4 filing is a routine insider transaction report common across all publicly traded companies. It reflects standard compensation practices for non-employee directors, where equity awards like RSUs are used to align director interests with long-term shareholder value. In the biotechnology and synthetic biology sector, such equity-based compensation is a common practice to attract and retain experienced board members.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as part of non-employee director compensation is a standard practice across various industries, including biotechnology.
• Companies like Moderna (MRNA), Illumina (ILMN), and other life sciences firms frequently utilize similar equity-based compensation structures to incentivize directors and align their interests with company performance.
• The vesting schedule tied to continued service and annual meeting dates is also typical for such programs, ensuring director commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may signal confidence and better alignment of interests.

Next Steps

• The company will hold its next Annual Meeting of Shareholders shortly after June 11, 2025, as indicated by the RSU vesting schedule.

Key Dates

Recommendation

Keywords

Ginkgo Bioworks Holdings, DNA, Form 4, SEC filing, insider transaction, restricted stock units, RSU conversion, director compensation, beneficial ownership, Kathy Hopinkah Hannan